We included studies that evaluated the performance of the most recent generation of commercial, RD1 antigen-based IGRAs (QFT-GIT and T-SPOT) among adults (age $15 years) with suspected active pulmonary tuberculosis or confirmed tuberculosis in low- and middle-income countries [22]; the World Bank Country Classification was considered as a surrogate for national tuberculosis incidence. HIV infection was established either by documented serological testing or self-report. We excluded (1) studies that evaluated noncommercial (in-house) IGRAs, purified protein derivative–based IGRAs, QuantiFERONTB Gold (2G), and IGRAs performed using specimens other than blood; (2) longitudinal data focused on the effect of antituberculosis treatment on IGRA response; (3) studies including ,10 eligible individuals; (4) studies focused on extrapulmonary tuberculosis or.
